Endo International plc / DAVA Pharmaceuticals, Inc.

Specialty Generics (Women's Health, Oncology, Transplant Injectables)

$28.4B US specialty generics market 2024 ($28.4B)

Disease Overview

Specialty generics are off-patent versions of complex or limited-competition drugs — typically injectables, controlled substances, or specialty oral products that require focused manufacturing and distribution capabilities. The category spans oncology supportive care, women's health, transplant immunosuppression and similar therapeutic areas where barriers to entry preserve margin.

Competitive Landscape

In 2014 the specialty generics segment was consolidating rapidly. Endo's main competitors included Mylan (after Agila), Hospira (the injectable specialist subsequently acquired by Pfizer for $17B in 2015), Sun Pharma–Ranbaxy, Teva (post-Cephalon and Actavis Generics), and Akorn. DAVA brought 13 commercial products, ~$131M of 2013 revenue and ~$100M adjusted EBITDA — implying a ~5.75x revenue multiple and ~5.75x EBITDA, attractive for a high-margin specialty generic asset. The portfolio centered on niche injectables and limited-competition oral products in women's health, oncology supportive care and transplant. Strategically, the deal extended Endo's then-CEO Rajiv De Silva's roll-up thesis at Endo Generics (formed via the Qualitest acquisition), positioning Endo as a top-five US generics player ahead of its later Par Pharmaceutical acquisition. The deal mattered because it added immediately accretive EBITDA, a near-term pipeline of >5 products expected in 2015 plus 20+ over subsequent years, and pricing-power exposure that became central to Endo's business mix until the post-2015 generic-pricing collapse.